Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/23/2025

Corticosteroid Use in Crohn's Disease Management

Efficacy and Safety

  • The European Society of Gastrointestinal Endoscopy recommends systemic corticosteroids for inducing remission in moderate to severe Crohn's disease, with a maximum treatment duration of 8 weeks 1
  • Corticosteroids effectively induce clinical remission in active Crohn's disease, with remission rates of 60-83% compared to 30-38% with placebo, according to the American Gastroenterological Association 2
  • Systemic corticosteroids, such as prednisolone 40-60 mg/day, are suggested for moderate to severe disease, with treatment duration not exceeding 8 weeks, as recommended by the European Crohn's and Colitis Organisation 1, 3
  • Budesonide 9 mg once daily for 8 weeks is as effective as prednisolone for mild ileocaecal Crohn's disease, with significantly fewer side effects, according to the National Institute for Health and Care Excellence 4

Adverse Effects and Safety Concerns

  • The American College of Gastroenterology states that corticosteroids cause significantly more adverse events than placebo, with risks increasing substantially with prolonged use 6
  • Prolonged corticosteroid use is associated with increased mortality, with a significant risk increase above 3000 mg prednisolone equivalent per year, as reported by the European Society of Gastrointestinal Endoscopy 7

Critical Management Principles

  • The American Gastroenterological Association recommends considering initiation or change of advanced therapy, such as biologics or immunomodulators, when prescribing systemic corticosteroids 1
  • Repeated courses of steroids should be avoided unless futility of other effective therapies has been established and surgical options are unavailable, according to the European Crohn's and Colitis Organisation 1, 6
  • Immunomodulators, such as azathioprine or methotrexate, should be considered for patients requiring two or more steroid courses within a calendar year, as recommended by the National Institute for Health and Care Excellence 2, 8

Disease-Specific Considerations

  • For colonic Crohn's disease, systemic corticosteroids, such as prednisolone 40 mg tapering by 5 mg weekly, are effective, but budesonide has no evidence of benefit in distal colonic inflammation, according to the European Society of Gastrointestinal Endoscopy 4
  • For hospitalized patients with severe disease, intravenous methylprednisolone 40-60 mg/day is suggested, with response assessment within 1 week to determine need for therapy modification, as recommended by the American College of Gastroenterology 3